Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission

NCT02395666 is registered in ClinicalTrials.gov with Giselle Sholler as lead sponsor.

NCT NCT02395666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02395666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission
Lead sponsor
Giselle Sholler
Phase
Phase 2
Overall status
Completed
Start date
March 5, 2015
Completion date
August 24, 2023
Enrollment
140 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma